Table 1.
Characteristics of the study cohort in the year 2012. 585 patients participated. Lupus medication includes NSAIDs, steroids, antimalarials, azathioprine, methotrexate, leflunomide, ciclosporine A, mycophenolic acid, cyclophosphamide, rituximab and belimumab.
| % (n) | Mean (SD) | Median (IQR) | Range | |
|---|---|---|---|---|
| Female | 94.4 (552) | |||
| Age | 53.3 (12.3, ) | 50 (17) | 14–87 | |
| Disease duration (years) | 17.7 (7.9) | 16 (11) | 7–51 | |
| Symptoms to first physicians visit (month) | 13.2 (40.9) | 2 (5) | 0–336 | |
| Physicians visit to diagnosis (month) | 34.0 (62.7) | 8 (36) | 0–576 | |
| Symptoms to diagnosis (month) | 47.2 (72.6) | 13 (56) | 0–576 | |
| Physical functioning (SF 36 PFI) | 67.0 (28.6) | 75 (45) | 0–100 | |
| Physical quality of life (SF-12 PCS) | 40.1 (12.0) | 41.1 (20.8) | 11.6–64.4 | |
| Mental quality of life (SF-12 MCS) | 46.4 (11.4) | 49.6 (17.8) | 16.3–68.2 | |
| Disease activity (SLAQ) | 13.0 (7.9) | 11 (11) | 0–42 | |
| Damage (BILD) | 2.5 (2.4) | 2 (3) | 0–12 | |
| Fatigue (FSS) | 4.1 (2.0) | 4.4 (3.4) | 1–7 | |
| Number of comorbidities | 1.7 (1.2) | 0 (2) | 0–10 | |
| Number of lupus medication | 1.8 (1.1) | 2 (2) | 0–5 | |
| Number of other medication | 2.6 (1.7) | 3 (2) | 0–8 | |
| Prednisolone ≤7,5 mg/d | 50.5 (294) | |||
| Prednisolone > 7,5 mg/d | 12.5 (73) |